Cargando…

Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery

Growth hormone (GH) secretion is regulated by various hormones or neurotransmitters, including gamma-aminobutyric acid. The aim of this study was to determine the propofol requirement in patients with GH-secreting pituitary tumors undergoing transsphenoidal surgery. General anesthesia was induced in...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Seung Hyun, Kim, Namo, Kim, Eui Hyun, Suh, Sungmin, Choi, Seung Ho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572689/
https://www.ncbi.nlm.nih.gov/pubmed/31035466
http://dx.doi.org/10.3390/jcm8050571
_version_ 1783427699120799744
author Kim, Seung Hyun
Kim, Namo
Kim, Eui Hyun
Suh, Sungmin
Choi, Seung Ho
author_facet Kim, Seung Hyun
Kim, Namo
Kim, Eui Hyun
Suh, Sungmin
Choi, Seung Ho
author_sort Kim, Seung Hyun
collection PubMed
description Growth hormone (GH) secretion is regulated by various hormones or neurotransmitters, including gamma-aminobutyric acid. The aim of this study was to determine the propofol requirement in patients with GH-secreting pituitary tumors undergoing transsphenoidal surgery. General anesthesia was induced in 60 patients with GH-secreting tumors (GH group, n = 30) or nonfunctioning pituitary tumors (NF group, n = 30) using an effect-site target-controlled intravenous propofol infusion. The effect-site concentrations were recorded at both a loss of consciousness and a bispectral index (BIS) of 40, along with the effect-site concentration after extubation, during emergence from the anesthesia. The effect-site concentration of propofol was higher in the GH group than in the NF group at a loss of consciousness and a BIS of 40 (4.09 ± 0.81 vs. 3.58 ± 0.67, p = 0.009 and 6.23 ± 1.29 vs. 5.50 ± 1.13, p = 0.025, respectively) and immediately after extubation (1.60 ± 0.27 vs. 1.40 ± 0.41, p = 0.046). The total doses of propofol and remifentanil during anesthesia were comparable between the groups (127.56 ± 29.25 vs. 108.64 ± 43.16 µg/kg/min, p = 0.052 and 6.67 ± 2.89 vs. 7.05 ± 1.96 µg/kg/h, p = 0.550, respectively). The propofol requirement for the induction of a loss of consciousness and the achievement of a BIS of 40 is increased during the induction of general anesthesia in patients with GH-secreting tumors.
format Online
Article
Text
id pubmed-6572689
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-65726892019-06-18 Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery Kim, Seung Hyun Kim, Namo Kim, Eui Hyun Suh, Sungmin Choi, Seung Ho J Clin Med Article Growth hormone (GH) secretion is regulated by various hormones or neurotransmitters, including gamma-aminobutyric acid. The aim of this study was to determine the propofol requirement in patients with GH-secreting pituitary tumors undergoing transsphenoidal surgery. General anesthesia was induced in 60 patients with GH-secreting tumors (GH group, n = 30) or nonfunctioning pituitary tumors (NF group, n = 30) using an effect-site target-controlled intravenous propofol infusion. The effect-site concentrations were recorded at both a loss of consciousness and a bispectral index (BIS) of 40, along with the effect-site concentration after extubation, during emergence from the anesthesia. The effect-site concentration of propofol was higher in the GH group than in the NF group at a loss of consciousness and a BIS of 40 (4.09 ± 0.81 vs. 3.58 ± 0.67, p = 0.009 and 6.23 ± 1.29 vs. 5.50 ± 1.13, p = 0.025, respectively) and immediately after extubation (1.60 ± 0.27 vs. 1.40 ± 0.41, p = 0.046). The total doses of propofol and remifentanil during anesthesia were comparable between the groups (127.56 ± 29.25 vs. 108.64 ± 43.16 µg/kg/min, p = 0.052 and 6.67 ± 2.89 vs. 7.05 ± 1.96 µg/kg/h, p = 0.550, respectively). The propofol requirement for the induction of a loss of consciousness and the achievement of a BIS of 40 is increased during the induction of general anesthesia in patients with GH-secreting tumors. MDPI 2019-04-26 /pmc/articles/PMC6572689/ /pubmed/31035466 http://dx.doi.org/10.3390/jcm8050571 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Seung Hyun
Kim, Namo
Kim, Eui Hyun
Suh, Sungmin
Choi, Seung Ho
Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title_full Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title_fullStr Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title_full_unstemmed Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title_short Propofol Requirement in Patients with Growth Hormone-Secreting Pituitary Tumors Undergoing Transsphenoidal Surgery
title_sort propofol requirement in patients with growth hormone-secreting pituitary tumors undergoing transsphenoidal surgery
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6572689/
https://www.ncbi.nlm.nih.gov/pubmed/31035466
http://dx.doi.org/10.3390/jcm8050571
work_keys_str_mv AT kimseunghyun propofolrequirementinpatientswithgrowthhormonesecretingpituitarytumorsundergoingtranssphenoidalsurgery
AT kimnamo propofolrequirementinpatientswithgrowthhormonesecretingpituitarytumorsundergoingtranssphenoidalsurgery
AT kimeuihyun propofolrequirementinpatientswithgrowthhormonesecretingpituitarytumorsundergoingtranssphenoidalsurgery
AT suhsungmin propofolrequirementinpatientswithgrowthhormonesecretingpituitarytumorsundergoingtranssphenoidalsurgery
AT choiseungho propofolrequirementinpatientswithgrowthhormonesecretingpituitarytumorsundergoingtranssphenoidalsurgery